MEPs Slate EU Industry Practices In Report On Barriers To Medicines Access
Executive Summary
The European Parliament’s environment and public health committee has produced a set of recommendations for a new approach to tackling barriers to medicines in the EU. There’s a particular focus on pricing strategies, intellectual property, and delays to generic competition.
You may also be interested in...
Pharma Attacked For “Playing The System” Of EU Pediatric Rewards
As a public consultation on the impact of the EU Paediatric Regulation comes to an end, the French drug bulletin Prescrire has attacked pharma firms for taking advantage of the rewards and incentives provided in the regulation and paying only lip service to the need for new medicines for children.
MEPs And Health Advocates Pile The Pressure On EU Drug Pricing
A European Parliament committee has approved a report outlining some possible solutions to the question of access to expensive new drugs, while Health Action International and several other NGOs have put emphasis on the need to ensure that where drugs developed by private companies use publicly funded research, they really serve the public good.
UN Panel Report: Positions Still Polarized Over Medicines Access Barriers
The report by the independent panel shows that the companies that develop and produce medicines, and the non-governmental organizations working on health issues at local level, still disagree fundamentally on the best way to go about improving access to those medicines. While R&D firms are skeptical of the report’s recommendations, the feeling among NGOs seems to be that this report represents something of a landmark development in the access debate.